Conference Coverage
Conference Coverage
PARP inhibitor prolongs PFS in mCRPC
BARCELONA – The PROfound trial shows that targeted therapy can be effective against metastatic castration-resistant prostate cancer bearing DNA...
Conference Coverage
Treatment guided by remote readings works when used as intended
PHILADELPHIA –
Conference Coverage
Immunotherapies under investigation in newly diagnosed B-ALL
SAN FRANCISCO – Researchers are testing blinatumomab and inotuzumab ozogamicin as first-line treatment in B-cell acute lymphoblastic leukemia.
Conference Coverage
Immunotherapy duo extends survival in first line for advanced NSCLC
BARCELONA – Nivolumab and low-dose ipilimumab improved survival of patients with untreated advanced non–small cell lung cancer regardless of PD-L1...
Conference Coverage
Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers
PHILADELPHIA – The findings support monitoring of cardiac biomarkers in the initial phase of checkpoint inhibitor treatment to identify patients...
Conference Coverage
Adjuvant radiotherapy no better than salvage post prostatectomy
BARCELONA – Men who underwent prostatectomy fared just as well with observation and salvage radiotherapy as with adjuvant radiotherapy.
Conference Coverage
Patient-reported outcomes are here to stay
WASHINGTON – Despite growing interest in incorporating patient-reported outcomes into physician and hospital performance measures, officials are...
Conference Coverage
Cancer drug prices higher in U.S. than Europe; don’t correlate with clinical benefit
BARCELONA – Cancer drug prices are significantly higher in the United states than in Europe, and they don’t correlate with clinical benefit in...
Conference Coverage
RISE analyses highlight further youth vs. adult T2D differences
BARCELONA – New data delve further into the differences in insulin sensitivity and glucose response in youth and adults with type 2 diabetes.
Conference Coverage
OS benefit with pembrolizumab endures long-term in advanced NSCLC
BARCELONA – First-line pembrolizumab provides a durable long-term OS benefit, compared with that of chemotherapy, in patients with advanced...